Destiny Pharma is an innovative pharmaceutical company focused on the development of novel medicines that represent a totally different approach to infectious disease.

These novel medicines are being developed to address the growing and unmet demand for prophylaxis and treatment of life-threatening drug-resistant bacteria, often referred to as "superbugs".

An example of such a target is the bacterium that is responsible for many hospital-acquired infections, methicillin-resistant Staphylococcus aureus (MRSA). The emergence of MRSA strains in the community suggests that infections due to multidrug-resistant bacteria are set to rise even further.

Traditional research has failed to fully address these problems. Destiny is pursuing revolutionary approaches to the prevention and treatment of this public health crisis.